Anagrelid i Kwas acetylosalicylowy + dipirydamol: interakcja

Risk factors for bleeding include the use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, heparin, anagrelide, fibrinolytic therapy, and chronic use of NSAIDs) [see Drug Interactions ( 7.1 )].

Anagrelide Patients taking aspirin in combination with anagrelide are at an increased risk of bleeding.

Bleeding Risk Use of concomitant AGRYLIN and aspirin increased major hemorrhagic events in a postmarketing study.

Assess the potential risks and benefits for concomitant use of AGRYLIN with aspirin, since bleeding risks may be increased.

Aspirin and Drugs that Increase Bleeding Risk : Increased risk of bleeding with concomitant use.

Aspirin and Drugs that Increase Bleeding Risk Co-administration of single-dose or repeat-dose AGRYLIN and aspirin showed greater ex vivo anti-platelet aggregation effects than administration of aspirin alone [see Clinical Pharmacology (12.3) ] .

Therefore, the potential risks of the concomitant use of AGRYLIN with aspirin should be assessed, particularly in patients with a high-risk profile for hemorrhage, before treatment is initiated [see Warnings and Precautions (5.3) ] .